1-800-567-8911 or
604-682-5050
(Telephone interpreting in over 150 languages available)
Indacaterol + glycopyrronium bromide + mometasone
Trade Name:
Enerzair Breezhaler
Manufacturer/Distributor:
Novartis Pharmaceuticals
Classification:
Asthma medication
ATC Class:
R03AL12 - indacaterol, glycopyrronium bromide and mometasone
Status:
active
Notice of Compliance (yyyy/mm/dd):
2020/07/02
Date Marketed in Canada (yyyy/mm/dd):
2020/11/05
Presentation:
Powder capsule for inhalation: 150 mcg indacaterol, 50 mcg glycopyrronium, 160 mcg mometasone. DIN: 02501244
Comments:
Used as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a medium or high dose of an inhaled corticosteroid.
Back to:
Drug Product Listings 
